| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826422 | Current Opinion in Pharmacology | 2012 | 5 Pages |
Abstract
⺠No clear evidence for recommending specific treatment with n-3 PUFA in CABG. ⺠General recommendations for the secondary prevention with n-3 should be applied. ⺠There is no evidence to advise patients to stop taking n-3 PUFA prior to CABG. ⺠It is unclear whether intake of n-3 PUFA is associated with wound healing problems.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Jan Jesper Andreasen, Erik Berg Schmidt,